Skip to main content
A logo

Agilent Technologies, Inc. (A) Stock: Price, Forecast & Analyst Target

Agilent Technologies, Inc. (A) — MoonshotScore 83/100 (Exceptional band), calculated Nov 18, 2026. Price $175.34 (-1.12%), as of the Nov 19, 2026 trading session; market cap $49.4B. Expected results Nov 23, 2026.

Educational signal · not a buy or sell recommendation · How to read this

$175.34 −$1.99 (-1.12%) Market Cap $49.4B

Agilent Technologies, Inc. · A · NYSE · Healthcare · Medical - Diagnostics & Research

Research dated 2026-09-12: Agilent Technologies equips laboratories with analytical instruments, diagnostics and genomics tools, then supports their operation through CrossLab consumables and services. Its economics therefore depend on both laboratory investment and continuing use of installed workflows. Recent growth and profit expansion make demand durability—and the timing of management’s anticipated reshoring benefit—the key issue to follow.

Price as of Nov 19, 2026

Key Statistics

83 of 100

MoonshotScore v2 · Agilent Technologies (A)

Exceptional
Business Quality Elite (87)
Financial Safety Okay (56)
Valuation Full (42)
Growth Durability Compounding (83)
Momentum Surging (91)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality and durable growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Full; Growth Durability: Compounding; Momentum: Surging.

  • EPS beat 0 of the last 4 reports
  • expected results Nov 23, 2026
  • Altman Z 5.75 · Piotroski F 6

Helping: business quality, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for A (57 recorded, newest six shown)
RecordedScoreBand
82Exceptional
81Exceptional
82Exceptional
82Exceptional
83Exceptional
83Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$175.34
Change on the day-1.12%
52-week range$108.35–$182.99
Market capitalisation$49.4B—
Price / earnings (trailing)33.83
Shares traded on the day2.13M
Beta (volatility vs the S&P 500)1.24

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $110, high $175, latest $175. $175 $110 high $175 Oct 17, 2025 Nov 19, 2026 · $175 $142Oct 17, 2025$146Oct 31, 2025$147Nov 14, 2025$154Nov 28, 2025$140Dec 12, 2025$138Dec 26, 2025$149Jan 9, 2026$135Jan 23, 2026$130Feb 6, 2026$123Feb 20, 2026$115Mar 6, 2026$111Mar 20, 2026$115Apr 2, 2026$122Apr 17, 2026$115May 1, 2026$112May 15, 2026$136May 29, 2026$130Jun 12, 2026$136Jun 26, 2026$134Jul 10, 2026$139Jul 24, 2026$146Aug 7, 2026$159Aug 21, 2026$151Sep 4, 2026$156Sep 18, 2026$168Oct 2, 2026$173Oct 16, 2026$175Oct 30, 2026$174Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Agilent Technologies (A): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Neutral
Valuation Neutral
Growth Durability Strong
Momentum Strong

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Fairly Valued
Profit Margin Moderate
Revenue Growth Neutral
Debt/Equity Neutral
ROE Strong
Gross Margin Moderate

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Agilent Technologies (A), and what does it report?

Short answer · as of

Agilent is not simply a diagnostics company. It sells chromatography, mass spectrometry, spectroscopy and cell-analysis systems to life-science and applied-markets laboratories; diagnostics and genomics products span tissue staining, genetic analysis, sequencing preparation and custom oligonucleotides.

CrossLab adds columns, sample-preparation supplies, software, compliance support, asset management and laboratory services.

Reported revenue consequently blends instrument purchases with consumables and service activity tied to laboratory operations. CrossLab is the largest disclosed segment, making recurring laboratory support economically important alongside demand for new systems.

2 · Latest results

What do the latest results show for Agilent Technologies (A)?

Revenue, gross profit and operating profit have risen sequentially across the latest reported periods, while net income and diluted earnings also recovered from the recent low. The latest result exceeded revenue and earnings expectations, extending the improvement seen in the preceding report after an earlier shortfall.

The statements show the recovery but do not isolate its operating cause. Management raised its fiscal revenue outlook and said pharma reshoring should begin producing more meaningful orders around year-end, with revenue building later; that frames reshoring as an emerging contributor rather than an explanation for all of the current improvement.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Jul 31, 2026Not availableNot availableNot availableNot available
Apr 30, 2026Not availableNot availableNot availableNot available
Jan 31, 2026Not availableNot availableNot availableNot available
Oct 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Jul 2025$1.74B$336M$1.18 (diluted)
Q4 FY2025$1.86B$434M$1.53 (diluted)
Q1 FY2026$1.80B$305M$1.07 (diluted)
Q2 FY2026$1.83B$339M$1.20 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Agilent Technologies (A)?

Short answer

Cash and short-term investments were $0.00 at the Jul 31, 2026 balance-sheet date. This figure does not establish a cash runway.

Agilent remains profitable and consistently generates positive operating cash flow, with the latest period showing a sharp cash-generation rebound. Cash and short-term investments have also increased over the reported span, while liquidity ratios indicate ample coverage of near-term obligations.

Debt nevertheless exceeds cash and investments, leaving Agilent in a net-debt position. That matters because the shares trade at a substantial earnings and sales valuation: weakening laboratory demand could pressure instrument revenue while selling and research costs continue, making sustained profit conversion more important than revenue growth alone. Distress and operating-quality screens are presently constructive, but they do not remove that valuation sensitivity.

Data-derived red flags

  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
  • Rich valuation — a P/E of 33.83 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
4 · What to check next?

What should you watch next at Agilent Technologies (A)?

Short answer · as of

The next earnings report is expected on Nov 23, 2026.

Watch whether revenue and operating profit continue their recent sequential climb, whether operating cash flow holds near its stronger recent level, and whether another earnings report clears market expectations. A reversal in any of those measures would weaken the evidence that the recovery is broadening.

Management has supplied a more company-specific checkpoint: pharma reshoring orders are expected to become more meaningful around year-end, followed by revenue contribution later. The useful confirmation would be visible order momentum that ultimately reaches reported sales, while the upcoming report provides the nearer test of the raised outlook.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Agilent Technologies compare with its peers?

Short answer

Agilent Technologies's score ranks 7th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Agilent combines complex analytical hardware with the supplies, software and services needed to keep laboratory workflows running. Compared with businesses dependent mainly on new equipment placements, CrossLab gives Agilent exposure to ongoing instrument use through columns, sample preparation, compliance, training and asset management.

Its diagnostics and genomics portfolio also reaches beyond analytical chemistry into tissue staining, genetic analysis and sequencing preparation. The relevant comparison is therefore not merely instrument breadth, but the mix of capital equipment, laboratory usage revenue and clinically oriented tools inside the same company.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
IDEXX Laboratories, Inc. (IDXX) Same industry, near in market value$689.65 Nov 19, 2026$54.3B96 5-pillar Nov 18, 2026
Edwards Lifesciences Corporation (EW) Named competitor$105.23 Nov 18, 2026$60.5B93 5-pillar Nov 18, 2026
Mettler-Toledo International Inc. (MTD) Same industry, near in market value$1705.66 Nov 19, 2026$33.9B93 5-pillar Nov 18, 2026
Medpace Holdings, Inc. (MEDP) Same industry, near in market value$646.87 Nov 18, 2026$18.1B92 5-pillar Nov 18, 2026
Cardinal Health, Inc. (CAH) Named competitor$272.37 Nov 19, 2026$63.0B88 5-pillar Nov 18, 2026
Illumina, Inc. (ILMN) Same industry, near in market value$210.01 Nov 18, 2026$31.8B84 5-pillar Nov 18, 2026
Agilent Technologies (A) — this page$175.34$49.4B83
Alcon Inc. (ALC) Named competitor$74.52 Nov 19, 2026$35.8B80 5-pillar Nov 18, 2026
Haleon plc (HLN) Named competitor$9.08 Nov 18, 2026$39.8B75 5-pillar Nov 18, 2026
Quest Diagnostics Incorporated (DGX) Same industry, near in market value$258.99 Nov 19, 2026$28.5B74 5-pillar Nov 18, 2026
IQVIA Holdings Inc. (IQV) Same industry, near in market value$257.84 Nov 18, 2026$42.5B71 5-pillar Nov 18, 2026
Labcorp Holdings Inc. (LH) Same industry, near in market value$370.78 Nov 18, 2026$30.1B71 5-pillar Nov 18, 2026
Becton, Dickinson and Company (BDX) Named competitor$212.73 Nov 19, 2026$57.9B68 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$150.00 – $195.00
Consensus target
$174.29
Median target
$177.50

Consensus record · Captured .

Measured against a quoted price of $175.34 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 8, 2026

Transactions
5
Identified insiders
4
Purchases
0
Sales
2
Other transactions
3

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held A in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Viking GlobalAndreas HalvorsenQ3 20260.92%$301.78MNew position
Bridgewater AssociatesFounded by Ray DalioQ3 20260.27%$61.28MAdded +1453.7% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Agilent Technologies (A)?

Read these with our analysis →

Agilent Technologies Healthcare Stock: Key Questions Answered

The last 2 questions are answered from this page's own dated data, not from the research.

Why does Agilent CrossLab matter to Agilent’s business model?

CrossLab sells laboratory consumables and operational services rather than relying on new instrument purchases alone. Its position as Agilent’s largest disclosed segment makes ongoing laboratory activity a major part of the company’s revenue mix.

What do Agilent’s chromatography and mass spectrometry systems measure economically?

They represent laboratory capital demand, but they also create workflows that use columns, sample-preparation products, software and support. Agilent participates in both the equipment decision and the continuing operation of the laboratory.

Is pharma reshoring already the main driver of Agilent’s growth?

Management described the more meaningful order benefit as approaching around year-end and the revenue contribution as building later. The current recovery should therefore be judged on reported performance without treating the anticipated reshoring benefit as fully realized.

What would confirm that Agilent’s recent earnings recovery is durable?

Further revenue and operating-profit progression, continued positive cash generation and delivery against the raised outlook would strengthen the case. Order momentum from pharma reshoring would add a distinct source of confirmation beyond another expectations beat.

What is the A stock price today?

The last price recorded for Agilent Technologies, Inc. (A), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the A price target?

The analyst consensus price target for Agilent Technologies, Inc. (A), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 24 figures on this page — 1 from SEC filings and earnings calls, 19 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Legal name; Business description; Revenue by segment; Quarterly income statement (USD thousands); Management outlook — dated call excerpts
  • 1. What is Agilent Technologies (A), and what does it report?: Sector / industry (provider taxonomy); Business description; Revenue by segment
  • 2. What do the latest results show for Agilent Technologies (A)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts
  • 3. What are the financial strengths and risks for Agilent Technologies (A)?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash against market value; Trailing twelve-month ratio set; Distress and quality screens; Quarterly income statement (USD thousands)
  • 4. What should you watch next at Agilent Technologies (A)?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters; Next earnings report; Analyst revenue and earnings estimates (average); Management outlook — dated call excerpts
  • 5. How does Agilent Technologies compare with its peers?: Business description; Revenue by segment; Sector / industry (provider taxonomy)
  • FAQ: Why does Agilent CrossLab matter to Agilent’s business model?: Business description; Revenue by segment
  • FAQ: What do Agilent’s chromatography and mass spectrometry systems measure economically?: Business description; Revenue by segment
  • FAQ: Is pharma reshoring already the main driver of Agilent’s growth?: Management outlook — dated call excerpts; Quarterly income statement (USD thousands)
  • FAQ: What would confirm that Agilent’s recent earnings recovery is durable?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold A

Funds in our ETF coverage that list A among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
Madison Covered Call ETF (CVRD)3.18%